Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of 9MW2821 with toripalimab versus 9MW2821 alone as first-line therapy for unresectable locally advanced or metastatic urothelial carcinoma
CTR20244701Phase 2Active
- Sponsor
- Mabwell
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bulumtatug fuvedotin, toripalimab in transitional cell carcinoma (TCC), sponsored by Mabwell. Started Jan 2025; status: active.
02
Drugs
bulumtatug fuvedotintoripalimab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20244701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244701.